ArticleScientific reports2026
Metabolomic and biochemometric profiling of Tecoma stans with mechanistic insights of its in vitro cytotoxic activity.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tecoma stans is an ornamental plant recognized for its diverse biological activities, including notable cytotoxic effects. This study integrates LC-MS/MS-guided biochemometric analysis with mechanistic cytotoxicity evaluation to prioritize metabolites potentially associated with the cytotoxic activity of T. stans leaves. The hydroalcoholic extract and its solvent fractions n-hexane (HEX), dichloromethane (DCM), and ethyl acetate (EAC) were assessed for in vitro cytotoxicity against human lung adenocarcinoma (A549) and ovarian carcinoma (SKOV-3) cell lines using the MTT assay. Comprehensive LC-MS/MS-based metabolomic profiling and biochemometric correlation analysis were performed on the DCM fraction. The major correlated compound, chrysoeriol (CRY), was isolated and, along with the DCM fraction, subjected to cell cycle analysis, apoptosis assays, scratch wound healing assays, and ELISA-based quantification of apoptotic and metastatic markers (caspase-3, p-STAT3, Bcl-2, and MMP-2) in SKOV-3 cells. The DCM fraction exhibited the highest potency, particularly against SKOV-3 cells (IC₅₀ = 18.50 µg/mL). Metabolomic profiling led to the annotation of 107 metabolites, where CRY, α-sulfoquinovosyl monoacylglyceride (α-SQMG), tecomanine, and hydroxyskytanthine were prioritized as metabolites potentially associated with cytotoxic activity. DCM induced pronounced sub-G₁ arrest (71.42%, P < 0.0005) and increased late apoptosis to 23.32%, whereas CRY elevated sub-G₁ accumulation to 48.02% and late apoptosis to 12.22% (P < 0.0005). Furthermore, both treatments markedly reduced scratch wound closure and modulated key signaling pathways through caspase-3 activation and suppression of p-STAT3, Bcl-2, and MMP-2. The CRY and DCM fraction of T. stans leaves exerted their cytotoxic effects against SKOV-3 cells through the induction of apoptosis, wound closure inhibition and modulation of key oncogenic proteins. This study provides the first biochemometric and mechanistic validation of T. stans leaves DCM fraction and CRY in SKOV-3 cells, highlighting the potential combined contribution of its phytochemical constituents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.